For the past several months, the U.S. government has been lambasted by AIDS activists for ostensibly failing to seek royalties from Gilead Sciences (GILD) for an expensive HIV prevention pill sold by the company and therefore not using the funds to help thwart the virus.

Now the federal government may have another chance — or yet another dispute may arise.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I have seen Truvada advertisements all over the media (print, online, and television). The advertisement, despite the disclaimers, almost promotes sex without condoms.
    It seems the advocates for the lower drug prices would save the people they are speaking for even more money if they pushed condom use more than trying to lower the cost of the drug. We seem so preoccupied with finding a cure, that prevention has gone the wayside.

  • Although the Federal government might have a right to royalties on its pre-exposure-prophylaxis-use patents on tenofovir- and emtricibatine-based antiretrovirals, a better, more effective strategy for trying to ensure affordable and equitable access to all 1.1 million-plus people who might benefits from PrEP in the United States would be to negotiate with Gilead to ensure that licenses are given (or taken by the government) that would allow for generic competition. Although generic prices for PrEP might not drop as low as the $60 per year price available from quality-assured generic producers for use in most low- and middle-income countries, very substantial savings from the $20,000 per person per year price in the US would be achieved if generic competition, including for new TAF/FTC combinations were allowed. The US paid for the PrEP clinical trials and has a patent on PrEP-use to boot. Isn’t this investment sufficient to justify government action and Gilead acquiescence to allow us to truly achieve dramatic reductions in new HIV infections that would result from affordable access to PrEP? Low prices, achieved through generic competition, would dramatically reduce the costs to government, insurers, and private individuals who need PrEP and the psycho-social services needed to support uptake, adherence, and monitoring of HIV status. It would be far easier to convince payers of the need for accelerated roll-out of PrEP if it did not cost a projected $20 billion a year in the US just to buy the quantity of PrEP needed at the price Gilead will otherwise charge. By the way, Gilead’s offer to gift some PrEP and to allow generic competition for TDF/FTC next year will provide minimal benefits as it continues to collect $20,000/pppy for “ungifted” patients on PrEP and as it switches former TDF/FTC PrEP users to its new TAF/FTC product Descovy that has a much longer period of monopoly protection.

  • Any life saving drug should be taken over by FDA, and manufactured by them. Price gouging is a no-no. Saying to patient pay 100k for your drug or die is not right.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy